BUZZ-BioRestorative Therapies up as FDA clears change to study on cell therapy

Reuters04-16

** Shares of BioRestorative Therapies rise 15.2% to $1.52 premarket

** Co says the U.S. FDA has cleared an amendment to the protocol of its ongoing mid-stage study on cell therapy candidate BRTX-100 for chronic lumbar disc disease (cLDD)

** Protocol amendment replaces saline injection in the placebo group with a sham injection - BRTX

** Co says the amendment removes the possibility of transient clinical outcomes in the placebo group

** "This positive change in our protocol will not have any impact from a timing perspective, affirming our already established 2024 enrollment completion target” - BRTX

** Up to last close, stock down 24% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment